Revance Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Revance Therapeutics' es Mark Foley , nombrado en Oct 2019, tiene una permanencia de 4.5 años. compensación anual total es $10.07M, compuesta por 7.2% salario y 92.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.06% de las acciones de la empresa, por valor de $3.64M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 4.8 años, respectivamente.
Información clave
Mark Foley
Chief Executive Officer (CEO)
US$10.1m
Compensación total
| Porcentaje del salario del CEO | 7.2% |
| Permanencia del CEO | 4.7yrs |
| Participación del CEO | 1.1% |
| Permanencia media de la dirección | 4.9yrs |
| Promedio de permanencia en la Junta Directiva | 5yrs |
Actualizaciones recientes de la dirección
Recent updates
What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You
Mar 04
Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain
Feb 29Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%
Dec 28Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be
Nov 10Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt
Aug 10Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors
Jun 14Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Apr 17Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt
Jan 02Revance Therapeutics submits sBLA for Daxxify for cervical dystonia
Oct 20Revance climbs 14% as FDA approves facial injectable for frown lines
Sep 08Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems
Aug 24Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?
Aug 04Revance: Potential Comeback On FDA Resubmission For DAXI
Jul 15Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt
Apr 17Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$325m |
| Dec 31 2023 | US$10m | US$720k | -US$324m |
| Sep 30 2023 | n/a | n/a | -US$403m |
| Jun 30 2023 | n/a | n/a | -US$346m |
| Mar 31 2023 | n/a | n/a | -US$341m |
| Dec 31 2022 | US$7m | US$673k | -US$356m |
| Sep 30 2022 | n/a | n/a | -US$274m |
| Jun 30 2022 | n/a | n/a | -US$263m |
| Mar 31 2022 | n/a | n/a | -US$274m |
| Dec 31 2021 | US$7m | US$660k | -US$281m |
| Sep 30 2021 | n/a | n/a | -US$297m |
| Jun 30 2021 | n/a | n/a | -US$303m |
| Mar 31 2021 | n/a | n/a | -US$292m |
| Dec 31 2020 | US$9m | US$650k | -US$282m |
| Sep 30 2020 | n/a | n/a | -US$249m |
| Jun 30 2020 | n/a | n/a | -US$209m |
| Mar 31 2020 | n/a | n/a | -US$186m |
| Dec 31 2019 | US$18m | US$190k | -US$159m |
| Sep 30 2019 | n/a | n/a | -US$155m |
| Jun 30 2019 | n/a | n/a | -US$146m |
| Mar 31 2019 | n/a | n/a | -US$143m |
| Dec 31 2018 | US$243k | n/a | -US$143m |
| Sep 30 2018 | n/a | n/a | -US$138m |
| Jun 30 2018 | n/a | n/a | -US$136m |
| Mar 31 2018 | n/a | n/a | -US$128m |
| Dec 31 2017 | US$338k | n/a | -US$121m |
Compensación vs. Mercado: La compensación total de Mark($USD10.07M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: La compensación de Mark ha aumentado mientras la empresa no es rentable.
CEO
Mark Foley (59 yo)
4.7yrs
Permanencia
US$10,068,915
Compensación
Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 4.7yrs | US$10.07m | 1.06% $ 3.0m | |
| CFO & Principal Accounting Officer | 5.6yrs | US$3.97m | 0.092% $ 259.2k | |
| Chief Legal Officer & General Counsel | 4.3yrs | US$3.53m | 0.046% $ 129.1k | |
| Head of Investor Relations & ESG | no data | sin datos | sin datos | |
| Senior Director of Investor Relations & Corporate Communications | 7.5yrs | sin datos | sin datos | |
| Vice President of Marketing | 5.2yrs | sin datos | sin datos | |
| Chief People Officer | 1.3yrs | sin datos | sin datos | |
| Head of Medical Affairs & Aesthetics | 6.1yrs | sin datos | sin datos | |
| Chief Medical Officer of Global Therapeutics Franchise Lead | 1.4yrs | sin datos | 0.0058% $ 16.3k | |
| Chief Commercial Officer | no data | sin datos | 0.11% $ 310.1k |
4.9yrs
Permanencia media
49yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RVNC se considera experimentado (4.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$10.07m | 1.06% $ 3.0m | |
| Independent Chairman | 10.3yrs | US$346.03k | 0.049% $ 139.1k | |
| Independent Director | 5yrs | US$317.53k | 0.042% $ 117.7k | |
| Independent Director | 7.9yrs | US$305.03k | 0.043% $ 121.8k | |
| Independent Director | 1.3yrs | US$421.49k | 0.020% $ 56.1k | |
| Independent Director | 3.3yrs | US$295.03k | 0.030% $ 85.5k | |
| Independent Director | 3.3yrs | US$304.18k | 0.030% $ 85.2k | |
| Independent Director | 4.9yrs | US$315.03k | 0.042% $ 117.7k |
5.0yrs
Permanencia media
65yo
Promedio de edad
Junta con experiencia: La junta directiva de RVNC se considera experimentada (4.8 años de antigüedad promedio).